Azvudine · FNC

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: COVID-19 in adult patients (conditional approval) (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:COVID-19 · Phase 3 · investigational in the US

Also approved (2)
CN
  • COVID-19 in adult patients (conditional approval)
  • HIV-1 infection, high viral load, combination therapy (conditional)
Product first approved 2021pmc.ncbi.nlm.nih.gov

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
COVID-19
HIV
Other / comorbidity
NCT07307586 · Zhigang Ren
2025-09-01 – 2027-12-31 · Chronic Hepatitis B, Azvudine
What this study did
Phase 2/3 (2)
COVID-19
NCT05689034 · Peking Union Medical College Hospital
2023-04-19 – 2025-12-31 · COVID-19 Respiratory Infection
What this study did
Phase 2 (2)
COVID-19
NCT05682599 · Shanghai Henlius Biotech
2023-01-06 – 2023-05-15 · COVID-19
What this study did
HIV
Phase 1 (9)
Other / comorbidity
NCT07001436 · Henan Genuine Biotech Co., Ltd.
2025-05-20 – 2025-09-30 · Renal Insufficiency
What this study did
NCT07002281 · Henan Genuine Biotech Co., Ltd.
2024-07-22 – 2025-03-20 · Healthy
What this study did
NCT07002255 · Henan Genuine Biotech Co., Ltd.
2021-12-20 – 2023-10-07 · Healthy
What this study did
NCT07002268 · Henan Genuine Biotech Co., Ltd.
2022-03-14 – 2023-08-31 · Healthy
What this study did
NCT06991634 · Henan Genuine Biotech Co., Ltd.
2023-04-08 – 2023-06-20 · Healthy
What this study did
NCT07001501 · Henan Genuine Biotech Co., Ltd.
2022-02-21 – 2023-03-13 · Healthy
What this study did
NCT07002242 · Henan Genuine Biotech Co., Ltd.
2022-07-06 – 2023-02-21 · Healthy
What this study did
NCT07001488 · Henan Genuine Biotech Co., Ltd.
2022-02-21 – 2023-01-01 · Healthy
What this study did
NCT07002229 · Henan Genuine Biotech Co., Ltd.
2021-12-09 – 2022-09-09 · Healthy
What this study did
Phase 4 (1)
COVID-19
NCT05697055 · Shandong Provincial Hospital
2023-01-21 – 2023-07-21 · COVID-19
What this study did
Early phase / not applicable (2)
COVID-19
NCT05642910 · Southeast University, China
2022-10-18 – 2023-04-30 · SARS-CoV-2 Infection
What this study did
NCT04425772 · Henan Genuine Biotech Co., Ltd.
2020-06-12 – 2020-08-12 · COVID-19
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 8 of them ahead of this one.

This drug's own stage for COVID-19: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Azvudine (FNC): this drugPhase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow FNC (Azvudine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Chronic Hepatitis B, AzvudineRecruiting
Est. primary completion 2026-12-31 · NCT07307586 · CT.gov ↗
What to watch

See the full readout calendar ↗